Achaogen (AKAO) Misses Q1 EPS by 17c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Guggenheim Downgrades Achaogen (AKAO) to Neutral Citing Valuation
May 7, 2018 7:46 AM EDTGuggenheim downgraded Achaogen (NASDAQ: AKAO) from Buy to Neutral.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $11.71 Friday.
... MoreAchaogen (AKAO) PT Lowered to $16 at SunTrust Robinson Humphrey
May 3, 2018 8:37 AM EDTSunTrust Robinson Humphrey lowered its price target on Achaogen (NASDAQ: AKAO) to $16.00 (from $27.00) while maintaining a Buy rating.
... MoreAchaogen (AKAO) PT Lowered to $19 at H.C. Wainwright
May 3, 2018 7:45 AM EDTH.C. Wainwright lowered its price target on Achaogen (NASDAQ: AKAO) to $19.00 (from $29.00) while maintaining a Buy rating.
... MoreAchaogen (AKAO) PT Lowered to $20 at Mizuho Securities
May 3, 2018 4:03 AM EDTMizuho Securities lowered its price target on Achaogen (NASDAQ: AKAO) to $20.00 (from $28.00) while maintaining a Buy rating.
... MoreAchaogen (AKAO) to Resume Trading at 5:40 pm ET
May 2, 2018 5:20 PM EDTAchaogen (NASDAQ: AKAO) to Resume Trading at 5:40 pm ET
... MoreAchaogen (AKAO) Provides Summary of FDA Advisory Committee Votes on Plazomicin
May 2, 2018 5:13 PM EDTAchaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee voted on the two points for Advisory Committee consideration as follows:
1. Has the applicant provided substantial evidence of the safety and effectiveness of plazomicin for the treatment of complicated urinary tract... More
Achaogen (AKAO) Confirms Stock Halted Ahead of FDA Panel to Review Plazomicin
May 2, 2018 7:24 AM EDTAchaogen, Inc. (NASDAQ: AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that NASDAQ has halted trading of the Companys common stock.
The U.S. Food and Drug Administrations (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) is meeting today to review plazomicin, which was developed for the treatment of adults with complicated urinary tract infections and... More
Achaogen (AKAO) Halted, News Pending
May 2, 2018 6:59 AM EDTAchaogen (NASDAQ: AKAO) Halted, News Pending
... More